GlaxoSmithKline (GSK) Raised to Buy at Beaufort Securities

GlaxoSmithKline (LON:GSK) was upgraded by Beaufort Securities to a “buy” rating in a report issued on Thursday. The firm currently has a GBX 1,500 ($21.03) target price on the stock, up from their prior target price of GBX 1,450 ($20.33). Beaufort Securities’ target price would suggest a potential upside of 14.70% from the stock’s previous close.

GSK has been the topic of several other reports. Goldman Sachs Group reissued a “buy” rating and issued a GBX 1,900 ($26.64) target price on shares of GlaxoSmithKline in a report on Tuesday, October 17th. S&P Global set a GBX 1,500 ($21.03) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a report on Thursday, October 26th. HSBC reissued a “buy” rating and issued a GBX 1,925 ($26.99) target price on shares of GlaxoSmithKline in a report on Wednesday, November 22nd. Morgan Stanley set a GBX 1,450 ($20.33) target price on GlaxoSmithKline and gave the stock a “sell” rating in a report on Monday, November 6th. Finally, Kepler Capital Markets dropped their target price on GlaxoSmithKline from GBX 1,520 ($21.31) to GBX 1,340 ($18.79) and set a “reduce” rating on the stock in a report on Wednesday, November 1st. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 1,542.95 ($21.63).

Shares of GlaxoSmithKline (GSK) opened at GBX 1,307.80 ($18.34) on Thursday. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($17.32) and a 1-year high of GBX 1,724.50 ($24.18). The company has a market capitalization of $65,780.00 and a price-to-earnings ratio of 4,218.71.

GlaxoSmithKline (LON:GSK) last released its earnings results on Wednesday, February 7th. The company reported GBX 111.80 ($1.57) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 110.90 ($1.55) by GBX 0.90 ($0.01). GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%. The business had revenue of GBX 763.90 billion for the quarter.

In other news, insider Patrick Vallance sold 20,000 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). Also, insider Sir Roy Anderson purchased 562 shares of the stock in a transaction dated Wednesday, February 7th. The shares were acquired at an average cost of GBX 1,278 ($17.92) per share, for a total transaction of £7,182.36 ($10,070.61). Over the last ninety days, insiders have bought 581 shares of company stock worth $743,284.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit